Movement Disorders Archives

Phase III Results Set Neurocrine Up for Huntington’s Chorea sNDA

American Academy of Neurology (AAN) Annual Meeting, Brain Diseases, Chorea, Clinical Trials, Dyskinesia, Genetic Brain Disease, Huntington’s Disease, Movement Disorders, R&D, Supplemental New Drug Application (sNDA), Therapeutics

Neurocrine Biosciences announced positive results from the company’s Phase III KINECT-HD study evaluating the efficacy of valbenazine in the treatment of chorea associated with Huntington’s Disease (HD).

April 1, 2022/by BioSpace

FDA Approves Austedo for Tardive Dyskinesia

Approvals, Chorea, FDA, FDA/Regulatory, Gastrointestinal Conditions, Huntington's Disease, Mental Health, Movement Disorders, New Indications, Tardive Dyskinesia

Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.

August 30, 2017/by Business Wire